153
Participants
Start Date
September 23, 2016
Primary Completion Date
May 14, 2019
Study Completion Date
May 14, 2019
Atezolizumab
Atezolizumab 1200 mg was administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression, loss of clinical benefit, or unacceptable toxicity (up to a total of 2 years of atezolizumab treatment).
Eastchester Center for Cancer Care, The Bronx
Stony Brook University Medical Center, Stony Brook
Cancer Treatment Centers of America - Eastern Regional Medical Center, Philadelphia
Inova Health Care Services, Falls Church
Levine Cancer Institute-Carolinas Medical Center; Levine Cancer Institute-Carolinas Medical Center, Charlotte
Florida Hospital, Orlando
Memorial Regional Hospital, Hollywood
The Cleveland Clinic Foundation, Cleveland
Franciscan St. Francis Health; Research Services, Indianapolis
Michigan Cancer Rsch Cons, Ypsilanti
University of Wisconsin, Madison
Virginia Piper Cancer Inst, Minneapolis
Avera Research Institute, Sioux Falls
St. Alexius Medical Center, Hoffman Estates
Quincy Medical Group; Canc Ctr at Blessing Hosp, Quincy
Cancer Center of Kansas, Wichita
Univ of Texas SW Medical Ctr, Dallas
San Juan Oncology Associates, Farmington
Veterans Affairs Central California Health Care System, Fresno
Western WA Oncology Inc PS, Lacey
Lead Sponsor
Genentech, Inc.
INDUSTRY